Journal: European Journal of Nuclear Medicine and Molecular Imaging

Article Title: Preclinical targeting of liver fibrosis with a 89 Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β

doi: 10.1007/s00259-024-06785-9

Figure Lengend Snippet: (Immuno)histochemical analysis of human liver tissue at various fibrotic stages. Top row: (Picro)Sirius Red (SR). Second row: α-SMA. Third row: PDGFRβ by commercial IgG and fourth row: PDGFRβ by Fibrobody®. Left to right: ( A ) Normal liver. ( B ) Early periportal fibrosis secondary to biliary compression due to adjacent adenoma. ( C ) Active cirrhosis secondary to autoimmune hepatitis. ( D ) Extinguished cirrhosis secondary to HCV infection, 10 years after start of antiviral pharmacotherapy. 3.5-fold digital zoom. Black bar in the bottom signifies 1 mm. Data acquired via screenshots of digital scans, using NDP.view2 software (Hamamatsu Photonics, Hamamatsu, Japan)

Article Snippet: Data acquired via screenshots of digital scans, using NDP.view2 software (Hamamatsu Photonics, Hamamatsu, Japan). ( B ) PET-CT scans at the end of treatment, 24 h after injection of 15 nmol/kg [ 89 Zr]Zr-SP02SP26-ABD or construct [ 89 Zr]Zr-R2R2-ABD.

Techniques: Infection, Software

Journal: European Journal of Nuclear Medicine and Molecular Imaging

Article Title: Preclinical targeting of liver fibrosis with a 89 Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β

doi: 10.1007/s00259-024-06785-9

Figure Lengend Snippet: (Immuno)histochemistry of liver tissues of mice on control diet (0 group), or 1, 2, 3 or 4 weeks on DDC diet. Results of representative animals (10x digital overview, same animal top to bottom). H&E: Haematoxylin-Eosin. SR: (Picro)Sirius Red. Black bar in the bottom signifies 250 μm. Data acquired via screenshots of digital scans, using NDP.view2 software (Hamamatsu Photonics, Hamamatsu, Japan)

Article Snippet: Data acquired via screenshots of digital scans, using NDP.view2 software (Hamamatsu Photonics, Hamamatsu, Japan). ( B ) PET-CT scans at the end of treatment, 24 h after injection of 15 nmol/kg [ 89 Zr]Zr-SP02SP26-ABD or construct [ 89 Zr]Zr-R2R2-ABD.

Techniques: Immunohistochemistry, Control, Software

Journal: European Journal of Nuclear Medicine and Molecular Imaging

Article Title: Preclinical targeting of liver fibrosis with a 89 Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β

doi: 10.1007/s00259-024-06785-9

Figure Lengend Snippet: PET-CT scans and ex vivo biodistribution of [ 89 Zr]Zr-SP02SP26-ABD and control construct [ 89 Zr]Zr-R2R2-ABD in mice with liver fibrosis of different etiology. Liver fibrosis was induced by 4 weeks of DDC diet, 4 weeks of CCl4 treatment or 6 weeks of CDA-HFD diet. ( A ) (immuno)histochemistry of liver tissues of control mice and mice with liver fibrosis. Black bar in the bottom signifies 250 μm. Data acquired via screenshots of digital scans, using NDP.view2 software (Hamamatsu Photonics, Hamamatsu, Japan). ( B ) PET-CT scans at the end of treatment, 24 h after injection of 15 nmol/kg [ 89 Zr]Zr-SP02SP26-ABD or construct [ 89 Zr]Zr-R2R2-ABD. All scans were scaled to reflect the same injected 89 Zr dose ( C ) and ( D ) As in B, ex vivo biodistribution of [ 89 Zr]Zr-SP02SP26-ABD and [ 89 Zr]Zr-R2R2-ABD, respectively

Article Snippet: Data acquired via screenshots of digital scans, using NDP.view2 software (Hamamatsu Photonics, Hamamatsu, Japan). ( B ) PET-CT scans at the end of treatment, 24 h after injection of 15 nmol/kg [ 89 Zr]Zr-SP02SP26-ABD or construct [ 89 Zr]Zr-R2R2-ABD.

Techniques: Positron Emission Tomography-Computed Tomography, Ex Vivo, Control, Construct, Immunohistochemistry, Software, Injection